Xylem now expects full-year organic revenue growth to be in the range of 6 to 8 percent, and 9 to 11 percent on a reported basis. This represents an increase from the Company's previous full-yearXylem now expects full-year organic revenue growth to be in the range of 6 to 8 percent, and 9 to 11 percent on a reported basis.
Xylem (NYSE:XYL) reported quarterly earnings of $0.66 per share which beat the analyst consensus estimate of $0.62 by 6.45 percent. This is a 65 percent increase over earnings of $0.40 per share from the same period last
Companies Reporting Before The Bell
• Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter.
• Stellantis (NYSE:STLA) is expected to report earnings for its second quarter.
Shares of Xylem (NYSE:XYL) rose by 7.86% in the past three months. Before we understand the importance of debt, let us look at how much debt Xylem has.